P.A.W. Capital Corp Sells 500 Shares of AbbVie Inc. (NYSE:ABBV)

P.A.W. Capital Corp reduced its position in AbbVie Inc. (NYSE:ABBVGet Rating) by 8.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,500 shares of the company’s stock after selling 500 shares during the period. P.A.W. Capital Corp’s holdings in AbbVie were worth $842,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Intelligent Financial Strategies bought a new stake in shares of AbbVie in the 4th quarter valued at about $27,000. GoalVest Advisory LLC purchased a new position in shares of AbbVie in the 1st quarter valued at approximately $33,000. Joseph P. Lucia & Associates LLC purchased a new position in shares of AbbVie in the 1st quarter valued at approximately $34,000. Cordant Inc. purchased a new position in shares of AbbVie in the 1st quarter valued at approximately $42,000. Finally, Monumental Financial Group Inc. purchased a new position in shares of AbbVie in the 1st quarter valued at approximately $52,000. 68.25% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

Shares of ABBV opened at $140.31 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.75 and a debt-to-equity ratio of 4.15. The firm has a market cap of $248.08 billion, a PE ratio of 19.87, a price-to-earnings-growth ratio of 4.00 and a beta of 0.72. The company’s 50 day simple moving average is $142.13 and its 200-day simple moving average is $149.60. AbbVie Inc. has a 12-month low of $105.93 and a 12-month high of $175.91.

AbbVie (NYSE:ABBVGet Rating) last posted its quarterly earnings data on Friday, July 29th. The company reported $3.51 earnings per share for the quarter, beating analysts’ consensus estimates of $3.42 by $0.09. AbbVie had a net margin of 22.03% and a return on equity of 158.41%. The firm had revenue of $14.58 billion for the quarter, compared to analyst estimates of $14.64 billion. During the same period last year, the firm posted $3.11 EPS. AbbVie’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, equities analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Investors of record on Friday, October 14th will be given a dividend of $1.41 per share. This represents a $5.64 dividend on an annualized basis and a yield of 4.02%. The ex-dividend date of this dividend is Thursday, October 13th. AbbVie’s dividend payout ratio is presently 79.89%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research analyst reports. Morgan Stanley decreased their price objective on shares of AbbVie from $191.00 to $188.00 and set an “overweight” rating for the company in a research report on Monday, August 1st. Argus decreased their price objective on shares of AbbVie from $165.00 to $155.00 and set a “buy” rating for the company in a research note on Wednesday, August 24th. Barclays decreased their price objective on shares of AbbVie to $160.00 in a research note on Tuesday, August 9th. Piper Sandler decreased their price objective on shares of AbbVie from $160.00 to $155.00 in a research note on Friday, July 29th. Finally, Atlantic Securities decreased their price objective on shares of AbbVie from $178.00 to $162.00 and set a “neutral” rating for the company in a research note on Monday, August 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $159.35.

AbbVie Company Profile

(Get Rating)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Featured Stories

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.